Use of human pluripotent stem cell-derived cells for neurodegenerative disease modeling and drug screening platform.

Alzheimer’s disease CRISPR-Cas9 Huntington’s disease Parkinson’s disease amyotrophic lateral sclerosis disease modeling drug screening hiPSCs human-induced pluripotent stem cells multiple sclerosis neurodegenerative disease

Journal

Future medicinal chemistry
ISSN: 1756-8927
Titre abrégé: Future Med Chem
Pays: England
ID NLM: 101511162

Informations de publication

Date de publication:
06 2019
Historique:
pubmed: 5 6 2019
medline: 27 5 2020
entrez: 5 6 2019
Statut: ppublish

Résumé

Most neurodegenerative diseases are characterized by a complex and mostly still unresolved pathology. This fact, together with the lack of reliable disease models, has precluded the development of effective therapies counteracting the disease progression. The advent of human pluripotent stem cells has revolutionized the field allowing the generation of disease-relevant neural cell types that can be used for disease modeling, drug screening and, possibly, cell transplantation purposes. In this Review, we discuss the applications of human pluripotent stem cells, the development of efficient protocols for the derivation of the different neural cells and their applicability for robust

Identifiants

pubmed: 31161803
doi: 10.4155/fmc-2018-0520
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1305-1322

Auteurs

Juan Antonio Garcia-Leon (JA)

Departamento Biologia Celular, Genetica y Fisiologia, Facultad de Ciencias, Instituto de Investigacion Biomedica de Malaga-IBIMA, Universidad de Malaga, 29010 Malaga, Spain.
Centro de Investigacion Biomedica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain.

Javier Vitorica (J)

Centro de Investigacion Biomedica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain.
Departamento Bioquimica y Biologia Molecular, Facultad de Farmacia, Universidad de Sevilla, 41012 Sevilla, Spain.
Instituto de Biomedicina de Sevilla (IBiS)-Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, 41013 Sevilla, Spain.

Antonia Gutierrez (A)

Departamento Biologia Celular, Genetica y Fisiologia, Facultad de Ciencias, Instituto de Investigacion Biomedica de Malaga-IBIMA, Universidad de Malaga, 29010 Malaga, Spain.
Centro de Investigacion Biomedica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH